ColoAlert® Revenue Increases 152% Year Over Year BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 (GLOBE NEWSWIRE) Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics
Mainz Biomed (MYNZ) Reports Q1 Revenue of $250K, EPS of ($0 45) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ColoAlert® Revenue Increases 152% Year Over Year BERKELEY, Calif. and MAINZ, Germany, May 16, 2023 Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early. | May 16, 2023
EQS-News: Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
15.02.2023 - Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK 15.02.2023 / 09:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz . Seite 1